Analyst Ratings for Unity Biotechnology
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 4 analysts have published their opinion on Unity Biotechnology (NASDAQ:UBX) stock. The average price target is $7.0, implying an upside from the current price of $2.41. The average price target has increased by 75.0% over the past month.
August 09, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts predict an upside for Unity Biotechnology (NASDAQ:UBX) with an average price target of $7.0.
The average price target given by analysts suggests a significant upside for Unity Biotechnology. This indicates a positive outlook for the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100